

Seeking Therapeutic Interventions and Vaccine Innovations for Hepatitis B and Hepatitis D Viruses

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify infectious disease therapeutics and vaccines in European institutes, targeting Hepatitis B and Hepatitis D virus infection.



Further information

Our client wishes to identify technologies, research projects and spin-out companies at any stage of development, from basic research to Phase I, focusing on the treatment of Hepatitis B and/or Hepatitis D. **Vaccines, novel therapeutics and selective targeting of factors capable of suppressing viral replication are of specific interest.**

Research interests

Priority will be given to submissions aligned with one or more of our client's search criteria below:

- Therapeutic HBV and HDV vaccines
- Immunomodulatory therapeutics to induce sustained disease remission
- Covalently closed circular DNA (cccDNA) inhibitors or destabilizers
- HB S antigen secretion inhibitors targeting either viral or cellular factors
- Technologies targeting capsid assembly, such as capsid assembly modulators (CAMs) or core protein allosteric modulators (CpAMs)
- Agonists of Toll-like receptor 8 (TLR8), retinoic acid-inducible gene I (RIG-I) or stimulator of interferon genes (STING)




Jurisdictions of Interest

Only submissions from institutions in Europe, Africa and the Middle East will be considered.

Submission Information

Submission of one-page technology briefs and information on applicable pre- or post-spinout companies is encouraged. The submission form can be downloaded [here](#).

Opportunities sought

-  Technologies
-  Research projects
-  Spin-out companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **17th July 2020 - 12am GMT**

Have any questions?

Contact our team at discover@in-part.co.uk